Alerta

TREATING AMYOTROPHIC LATERAL SCLEROSIS HAVING ONSET 24 MONTHS PRIOR TO TREATMENT

Resumen de: MX2025000057A

The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

REGIMEN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS HAVING ONSET 24 MONTHS PRIOR TO TREATMENT

Resumen de: WO2024011094A1

The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

SUSTAINED RELEASE-MICROSPHERE FORMULATION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR

Resumen de: EP4552634A1

The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.

ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: EP4553069A1

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

PGAM5 Phmaceutical composition for treating Parkinson's disease containing cell-transducing PGAM5 fusion protein

Resumen de: KR20250064691A

과제: 부작용이 적거나 없으며, 효과가 우수한 파킨슨병 예방 또는 치료용 약제를 제공하는 것. 해결수단: 본 발명은 세포투과성 PGAM5 (포스포글리세레이트 뮤테이즈 5) 융합단백질을 포함하는 파킨슨병 치료용 약학 조성물에 관한 것으로서, 세포 내로 투과된 PGAM5 융합단백질이 MPP+로 유도한 도파민성 세포사멸과 파킨슨 동물 질환 모델에서 세포 보호효능을 발현하는지를 연구하였다. 그 결과, PGAM5 융합단백질은 파킨슨병에서 효과적인 단백질 치료제로서의 가능성이 있음을 확인하였다.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GENETIC PARKINSON'S DISEASE COMPRISING MITOCHONDRIA AS AN ACTIVE INGREDIENT

Resumen de: KR20250065159A

본 발명에서 파킨슨병을 효과적으로 치료할 수 있는 미토콘드리아 치료제를 제공한다. In vitro 실험 결과, 미토콘드리아 치료제(PN-101)는 신경독소에 의해 야기된 세포 사멸을 현저히 감소시켰다. 또한, PN-101은 LPS에 의해 유도된 항염증 사이토카인 발현을 완화시킴을 확인하였다. 뿐만 아니라, In vivo 실험 결과, PN-101은 DA 뉴런에서 신경 보호 효과를 나타내고, 미세아교세포 활성을 억제함으로써, MPTP 유발된 운동 이상을 개선할 수 있음을 확인하였다. 따라서, 미토콘드리아를 개체에 투여시 파킨슨병을 효과적으로 개선하거나 치료할 수 있음을 확인하였다.

COMPOSITION COMPRISING A MIXTURE OF DHA AND/OR EPA AND A PHOSPHOLIPID OF PLANT ORIGIN

Resumen de: US2025144159A1

A composition comprising a mixture of DHA and/or EPA in the form of glyceride or ethylester derived from at least one microorganism, such as a microalga, and at least one plant-derived phospholipid, in which the content of DHA and/or EPA in triglyceride form is between 10% and 90% by weight relative to the total weight of the composition, and the content of at least one plant-derived phospholipid, such as phosphatidylcholine, is between 10% and 90% by weight relative to the weight of composition. The method for manufacturing same and to the use thereof, in particular in the treatment of pathologies involving a deficiency of DHA and/or EPA, such as age-related macular degeneration or Alzheimer's disease.

Pharmaceutical composition for treating Alzheimer's disease containing senescent cell-targeting drug as an active ingredient

Resumen de: KR20250063452A

본 발명은 상염색체우성 알츠하이머병에서 노화 조절을 통한 아밀로이드 병리 제거에 최적 시기 및 방법을 확인하여 완성된 것으로서, 노화세포 표적 약물을 진행된 알츠하이머병 환자에 투여하여 알츠하이머병을 치료하는 방법 등을 제공하여 노화 조절을 통한 새로운 패러다임의 알츠하이머병의 치료적 접근을 가능하게 하며, 상기 방법의 효과적인 치료시기를 제공함으로써 진행된 알츠하이머병 환자를 대상으로 하는 다각적 치료방법의 하나로 이용될 수 있다.

ANTI-GAL3 ANTIBODIES AND METHODS OF USE

Resumen de: US2025145722A1

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES

Resumen de: WO2025093735A2

The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal/mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42/Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.

COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S DISEASE

Resumen de: WO2025097123A1

Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.

Humanized Anti-TDP-43 Binding Molecules and Uses Thereof

Resumen de: US2025145695A1

The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Resumen de: US2025146000A1

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

METHODS OF ENHANCING LEVODOPA THERAPEUTIC EFFICACY

Resumen de: WO2025097160A1

The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.

TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE

Resumen de: US2025144135A1

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE

Resumen de: AU2023367200A1

The present disclosure provides methods for achieving optimal levels of bevemipretide (also known as "(R)-2-amino-N-((S)- 1 -(((S)-5-amino- 1 -(3 -benzyl- 1,2,4-oxadiazol-5- yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5- guanidinopentanamide" or "SBT-272"), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, in brain tissue of subjects suspected of having, suffering from, or at risk for a neurodegenerative disease, such as, but not limited to amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), PD with dementia, dementia with Lewy bodies, Multiple System Atrophy, Huntington's disease, HTT proteinopathy, Frontotemporal Lobar Degeneration (FTLD), a tauopathy, and other disease where TDP-43, Tau protein, and α-synuclein are associated with the disease pathology.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMENTIA, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT

Resumen de: WO2025095553A1

A pharmaceutical composition for preventing or treating dementia diseases, containing, as an active ingredient, an isoquinoline derivative compound or a pharmaceutically acceptable salt thereof, of the present invention, does not induce cytotoxicity and can alleviate learning and memory abnormalities in an animal model of Alzheimer's dementia, and thus is expected to be effectively used in the development of therapeutic agents for dementia diseases.

KIT FOR DIAGNOSING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE

Resumen de: EP4549585A1

A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.

COMPOSITION AND METHOD FOR EVALUATING RESPONSIVENESS OF EDARAVONE

Resumen de: EP4549579A1

A composition of the present disclosure contains edaravone and is used for causing a change in expression level of a gene product in a target. The gene product is a gene product of one or more genes selected from KAZALD1, SBK1, SCN2A, UBE2L6, ALPL, NTM, PTTG1, ITGB4, HAUS4, DCTD, MT2A, ASF1B, FCSK, MAST1 and FAIM2. The composition is also suitably used as a pharmaceutical. The composition is also suitably used for treating or preventing a neurodegenerative disease. The neurodegenerative disease is suitably amyotrophic lateral sclerosis (ALS). The present disclosure also provides a method for evaluating responsiveness of edaravone based on an expression level of the gene product or a change in the expression level.

Heterocyclic compound

Resumen de: NZ746628A

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I) : wherein each symbol is as defined in the specification, or a salt thereof.

Detection of chromosome interactions

Resumen de: NZ776663A

A method of determining the epigenetic chromosome interactions which are relevant to a companion diagnostic. In particular, the present invention relates to an in vitro method for determining predisposition to amyotrophic lateral sclerosis in a person, wherein the method comprises detecting the presence or absence of epigenetic chromosome interaction markers.

TARGETING ALS-FUS AGGREGATION WITH PROTEASOME INHIBITORS

Resumen de: WO2025088613A1

Provided are methods of treating a subject having a disease characterized by accumulation of FUS -associated aggregates by administering to the subject a therapeutically effective amount of a proteasome inhibitor, an agent which upregulates SAT1, or an agent which upregulates spermine, thereby treating the subject. Also provided are proteasome inhibitors, an agent which upregulates SAT1, or an agent which upregulates spermine for use in treating a subject having a disease characterized by accumulation of FUS-associated aggregates, and methods of reducing accumulation of FUS-associated aggregates in cells of a subject, the method comprising contacting the cells of the subject with a proteasome inhibitor an agent which upregulates SAT1, or an agent which upregulates spermine, thereby reducing the accumulation of FUS-associated aggregates in the cells of the subject.

METHODS OF TREATMENT USING A TAU PET LEVEL

Resumen de: AU2023406056A1

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.

MEDICAL AGENT FOR TREATING OR SUPPRESSING PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: US2025134863A1

Disclosed is a medical agent for treating or suppressing progression of at least one symptom selected from a group consisting of amyotrophic lateral sclerosis and symptoms resulting from amyotrophic lateral sclerosis in a subject. The medical agent contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, or a hydrate or solvate thereof. A blood uric acid level of the subject before administration of the medical agent is 4.2 mg/dL or higher.

COMBINATION TREATMENT OF ALZHEIMER'S DISEASE

Nº publicación: WO2025087971A1 01/05/2025

Solicitante:

TREEWAY TW001 B V [NL]
TREEWAY TW001 B.V

Resumen de: WO2025087971A1

The invention relates to the treatment of Alzheimer's disease in a human patient, said treatment comprising administration of an anti-Aβ antibody component and co-administration of edaravone, the anti-Aβ antibody component being selected from anti-Aβ antibody, an Aβ- binding fragment of an Aβ antibody, a vectorised anti-Aβ antibody and a vectorised Aβ- binding fragment of an Aβ antibody.